Peripheral blood biomarkers in systemic sclerosis -associated interstitial lung diseases
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 1
Abstract
Interstitial lung disease (ILD) can lead to significant morbidity and excess mortality in systemic sclerosis (SSc) patients. The early identification of patients at risk of progressive ILD is the main challenges for treating this highly variable disease. Although high resolution CT (HRCT), lung function tests (PFTs), bronchial lavage fluid (BALF), lung biopsy can be used to detect SSc-ILD, it is necessary to find reliable predictors for the disease progression. Peripheral blood biomarkers offer the advantages of being readily obtained, non-invasive, and serially monitored. New insights during the past several years have underscored the epithelial and endothelial cell injury with inflammatory and immune activation impacting of clinically significant SSc-associated ILD, but the pathogenesis of SSc-ILD is unknown. Some serum biomarkers including SP-D, KL-6, IL-9, MMPs, MCP-1, Defensins, IL-8 CXCL10 and CCL18 have identified to be associated with SSc-ILD. Future more cohorts, well-designed and long-term studies are needed to find more prospective biomarkers that influence SSc-ILD disease progression.
Authors and Affiliations
Ciyuan Yu, Shuli Song, Juan Chen
Keywords
Related Articles
- EP ID EP603812
- DOI -
- Views 68
- Downloads 0
Sickle cell trait in orthopaedic surgery: A real issue or just a bogeyman
Sickle cell disease is a hereditary blood disease characterized by the production of abnormal haemoglobin. HbS precipitates in the red cells under specific circumstances. The sickle cell trait (SCT), long considered an a...
HLA class I and II alleles may influence susceptibility to adult dermatomyositis in a Mexican mestizo population
Objective: To investigate the possible association between HLA and Dermatomyositis (DM) in the Mexican mestizo population. Methods: HLA class I (A and B) and class II (DRB1* and DQB1*) were determined in 36 Mexican mest...
Nanomedicine in rheumatology: A new field in the diagnosis and therapy of rheumatic diseases
Nanomedicine is a prolific and vastly expanding field of medicine rendering important new avenues to improve diagnosis and treatment of human maladies. However, safety of the nanomaterials and therapeutic agents must be...
Influence of single nucleotide polymorphisms on the efficacy of platelet-rich plasma in the treatment of injuries
Tissue repair in musculoskeletal injuries is often a slow and sometimes incomplete process. Musculoskeletal injuries have a great impact on athletes’ especially elite athletes – and a rapid recovery of full efficiency an...
Rheumatology to hepatology cross talk: An evidence based update on the treat to target strategy in hepatitis-C related extrahepatic autoimmune syndromes
Hepatitis C virus (HCV) is a universally identified major epidemiological health problem with an estimated reservoir of almost 200 million or 3% of the global population. In the year 2013, the WHO declared viral hepatiti...